New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment

Low levels of two genes predicts positive response to chemotherapy and longer survival times —

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients. The results, published June 17 in PLOS ONE, revealed two genes that could help physicians make more informed treatment decisions for patients with this disease. …Read the full story from the UC San Diego Newsroom

Paul Fanta, MD, MS

Paul Fanta, MD, MS

Senior author of the study is Department of Medicine oncologist Paul Fanta, MD, MS, Health Sciences associate clinical professor in the Division of Hematology-Oncology. Dr. Fanta is a researcher in the Solid Tumor Therapeutics Program at the UC San Diego Moores Cancer Center.

Read the article in PLOS ONE (Open Access)

Blacks Have Less Access to Cancer Specialists, Treatment

UC San Diego Study Suggests Racial Inequality Leads to Higher Mortality

Researchers at the University of California, San Diego School of Medicine say metastatic colorectal cancer patients of African-American descent are less likely to be seen by cancer specialists or receive cancer treatments. This difference in treatment explains a large part of the 15 percent higher mortality experienced by African-American patients than non-Hispanic white patients. … Read the full story from the UC San Diego News Center


Department of Medicine co-investigators on the project are Samir Gupta, MD, MSCS, associate professor of clinical medicine in the Division of Gastroenterology; Gregory Heestand, MD, Health Sciences assistant clinical professor in the Division of Hematology-Oncology and Paul Fanta, MD, MS, Health Sciences associate clinical professor in the Division of Hematology-Oncology.

Samir Gupta, MD, MSCS  Gregory Heestand, MD  Paul Fanta, MD, MS
Above, from left: Drs. Samir Gupta, Gregory Heestand, and Paul Fanta

Citation for the study report in the Journal of the National Cancer Institute:

Daniel R. Simpson, María Elena Martínez, Samir Gupta, Jona Hattangadi-Gluth, Loren K. Mell, Gregory Heestand, Paul Fanta, Sonia Ramamoorthy, Quynh-Thu Le, and James D. Murphy. Racial Disparity in Consultation, Treatment, and the Impact on Survival in Metastatic Colorectal Cancer JNCI J Natl Cancer Inst first published online November 14, 2013 doi:10.1093/jnci/djt318  |  Full text (UCSD only)